3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Hepatoblastoma
1
Hemangioma, Cavernous, Central Nervous System
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
pembrolizumab
6
Radiosurgery
6
Nivolumab
6
Magnetic Resonance Spectroscopy
6
Ifosfamide
5
Bevacizumab
5
cabozantinib
4
Sunitinib
4
Sirolimus
4
Granulocyte Colony-Stimulating Factor
4
Etoposide
4
Carboplatin
4
Specimen Handling
3
Sorafenib
3
Paclitaxel
3
Melphalan
3
Ipilimumab
3
Cyclophosphamide
3
Busulfan
3
temsirolimus
2
lenvatinib
2
etoposide phosphate
2
cediranib
2
belzutifan
2
alectinib
2
Trastuzumab
2
Thiotepa
2
Stem Cell Transplantation
2
Radiotherapy
2
Oxaliplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Simvastatin
×
CNS
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled